Artemether injection

1 Pharmacology Artemether is a derivative of artemisinin, which has a strong and rapid killing effect on the erythrocytic stage of malarial parasites and can quickly control clinical attacks and symptoms. The mechanism of action of artemisinin is not very clear, but it mainly interferes with the function of mitochondria, the surface membrane of malarial parasites. Artemisinin changes the membrane structure of malarial parasites by affecting the ultrastructure of the erythrocytic stage. 2 Due to the effect on the food vesicle membrane, the nutritional intake of malarial parasites is blocked. When malarial parasites lose a large amount of cytoplasm and nutrients and cannot be replenished, they die quickly. Its mode of action is through its peroxide (dioxygen) bridge, mediated by the free iron produced after the decomposition of hemoglobin, to produce unstable organic free radicals and/or other electrophilic mediators, and then form covalent adducts with malarial parasite proteins, causing the death of malarial parasites. The antimalarial activity of artemether is 6 times greater than that of artemisinin. 3 Toxicology The LD50 of oral artemether in mice is 895-977 mg/kg, and the LD50 of intramuscular injection of artemether oil in rats is 597 mg/kg. Subacute toxicity tests show that rats were intramuscularly injected with artemether oil at 18 mg/kg per day for 14 days, and there were no other adverse reactions except for a decrease in the number of reticulocytes. This drug has a certain embryotoxicity, which is manifested as embryo absorption.

Main ingredients: Its chemical name is: (3R, 5aS, 6R, 8aS, 9R, 10S, 12R, 12aR)-decahydro-10-methoxy-3,6,9-trimethyl-3,12-oxo-12H-pyrano[4,3-j]-1,2-benzodiphenylamine. Molecular formula: C16H26O5 Molecular weight: 298.4

Colorless or light yellow clear oily solution.

It is suitable for the treatment of various types of malaria, including the treatment of chloroquine-resistant falciparum malaria, such as falciparum malaria and vivax malaria.

1 Common adult dose, intramuscular injection, first dose 160 mg, 80 mg once a day from the second day onwards, for 5 consecutive days. 2 Common pediatric dose, intramuscular injection, first dose 3.2 mg/kg body weight; from the second to the fifth day, 1.6 mg/kg body weight once a day.

This product has a mild reaction. Some patients may have a slight increase in aspartate aminotransferase and alanine aminotransferase, and a transient decrease in reticulocytes.

Not yet clear.

Not yet clear.

Protect from light, seal tightly and store in a cool place.

0.5ml:40mg

KPC Pharmaceuticals, Inc.

• Founded in:

  1995-12-14

• Address:

  No. 166, Keyi Road, High-tech Industrial Development Zone, Kunming, Yunnan Province

• Tax NO.:

  91530000216562280W

• Registered Funds:

  757.986969 yuan

• Website:

  Log in to view

• Email:

  Log in to view